Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
arcticnovartis
- Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-negative disease
- New 48-week efficacy and safety data from the Phase III APPLY-PNH trial of investigational oral monotherapy iptacopan in anti-C5-treated adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and persistent anemia
- Nearly 4 year follow-up efficacy and safety results from end of study treat